Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms
Sponsor study identifier
interventional
169
1 country
1
Study Start
February 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2009
Actual (reported)Study Completion
May 2009
Actual (reported)The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2003
Date type not reportedThis date has not been verified as actual or estimated.
August 11, 2005
Actual (reported)August 12, 2005
Actual (reported)May 2009
Actual (reported)May 2009
Actual (reported)Comparison of the imaging diagnosis, based on visual analysis and quantitative analysis, to the clinical diagnosis of the investigator blinded to the imaging results
5 years
Comparison of the DAT imaging diagnosis, initial diagnosis by the movement disorder experts and referral neurologist diagnosis to the 'gold standard' diagnosis
5 years
To assess \[123I\]ß CIT and SPECT imaging
Single Photon Emission Computed Tomography SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Institute for Neurodegenerative Disorders
New Haven, Connecticut, 06510, United States
Danna L Jennings, MD
Institute for Neurodegenerative Disorders
169 participants (actual enrollment reported by the registry).
First Submitted
August 11, 2005
First Posted
August 12, 2005
Study Start
February 2003
Date type not reportedThis date has not been verified as actual or estimated.
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
Contact the study team to confirm eligibility.
Primary Completion
May 2009
Actual (reported)Study Completion
May 2009
Actual (reported)Last Updated
July 16, 2014
Record last verified: 2014-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: